Brief: Armata Pharmaceuticals Says On March 13, Entered Into An Award Agreement With Cystic Fibrosis Foundation - SEC Filing
19/03/2020 22:10
March 19 (Reuters) - Armata Pharmaceuticals Inc ARMP.A :
* ARMATA PHARMACEUTICALS SAYS ON MARCH 13, ENTERED INTO AN
AWARD
AGREEMENT WITH CYSTIC FIBROSIS FOUNDATION - SEC FILING
* ARMATA PHARMACEUTICALS - PURSUANT TO AGREEMENT, CO
RECEIVED
DEVELOPMENT AWARD OF UP TO $5.0 MILLION
* ARMATA PHARMACEUTICALS - AWARD WILL BE USED TO FUND CO'S
PHASE
1B/2 CLINICAL TRIAL OF PSEUDOMONAS AERUGINOSA PHAGE CANDIDATE,
AP-PA02
Source : (http://bit.ly/2WucJji)
Further company coverage: ARMP.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Armata Pharmaceuticals
See all newsBrief: Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles